CurrentCignaPolicy N/A

Antiseizure Medications - Epidiolex Prior Authorization Policy

Defines prior authorization requirements and medical necessity criteria for coverage of Epidiolex (cannabidiol oral solution) for FDA‑approved and selected other seizure indications under Cigna benefit plans.

Policy Summary

PayerCigna

PolicyAntiseizure Medications - Epidiolex Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateFeb 11, 2026

Key ActionObtain prior authorization and document patient age, prior/concomitant antiseizure medications tried, and neurologist involvement; approvals are generally for one year when criteria are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3FDA‑approved indications listed

1 yearTypical approval duration

≥1 yrMinimum patient age

≥2Required other ASMs for initial therapy

Coverage Criteria for Epidiolex (cannabidiol)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

A or B: A) Initial Therapy OR B) Currently Receiving Epidiolex

A) Initial Therapy: i. Patient is ≥ 1 year of age; AND ii. Patient meets ONE of the following (a or b): a) Patient has tried or is concomitantly receiving at least two other antiseizure medications (examples include valproic acid, topiramate, clonazepam, levetiracetam, zonisamide); OR b) Patient has tried or is concomitantly receiving one of Fintepla (fenfluramine oral solution), Diacomit (stiripentol), or clobazam; AND iii. The medication is prescribed by or in consultation with a neurologist.

B) Currently Receiving: Patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.

Lennox‑Gastaut Syndrome (FDA‑approved)

Approve for 1 year if the patient meets ONE of the following (A or B):

A or B: A) Initial Therapy OR B) Currently Receiving Epidiolex

A) Initial Therapy: i. Patient is ≥ 1 year of age; AND ii. Patient has tried or is concomitantly receiving at least two other antiseizure medications (examples include lamotrigine, topiramate, rufinamide, felbamate, clobazam, valproic acid, levetiracetam, zonisamide, perampanel, vigabatrin); AND iii. The medication is prescribed by or in consultation with a neurologist.

B) Currently Receiving: Patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.

Tuberous Sclerosis Complex (FDA‑approved)

Approve for 1 year if the patient meets ONE of the following (A or B):

A or B: A) Initial Therapy OR B) Currently Receiving Epidiolex

A) Initial Therapy: i. Patient is ≥ 1 year of age; AND ii. Patient has tried or is concomitantly receiving at least two other antiseizure medications (examples include valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, rufinamide, felbamate, clobazam, perampanel, vigabatrin, everolimus); AND iii. The medication is prescribed by or in consultation with a neurologist.

B) Currently Receiving: Patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.

Other Uses with Supportive Evidence: Treatment‑Refractory Seizures/Epilepsy (Specific Rare Conditions)

Approve for 1 year if the patient meets ONE of the following (A or B):

A or B: A) Initial Therapy OR B) Currently Receiving Epidiolex

A) Initial Therapy: i. Patient is ≥ 1 year of age; AND ii. Patient has tried or is concomitantly receiving at least two other antiseizure medications (examples include valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, rufinamide, felbamate, clobazam, perampanel, vigabatrin); AND iii. The medication is prescribed by or in consultation with a neurologist.

Specific rare conditions covered include CDKL5 deficiency disorder; Dup15q, Aicardi, or Doose syndromes; febrile infection-related epilepsy syndromes; focal epilepsy; Sturge-Weber syndrome; lissencephaly; cortical malformation/dysplasia; and epilepsy with myoclonic absences.

B) Currently Receiving: Patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.

Prescriber Responsibilities and Authorization Rules

Prior Authorization

Prior authorization required

Prior authorization is recommended for prescription benefit coverage of Epidiolex; all approvals are provided for the duration noted (generally 1 year). Initial approval requires the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Approvals are generally granted for 1 year when criteria are met.

Step Therapy

Step therapy — try ≥2 other antiseizure medications

For initial therapy in all listed indications, the patient must have tried or be concomitantly receiving at least two other antiseizure medications (policy provides examples of qualifying ASMs).

Examples of other antiseizure medications are listed in each indication (e.g., valproic acid, topiramate, clonazepam, levetiracetam, zonisamide; additional examples vary by indication).

Documentation Required

Required documentation

Prescriber must document the patient's age and the prior or concomitant antiseizure medications tried (or, for patients currently receiving Epidiolex, evidence of response), and the medication must be prescribed by or in consultation with a neurologist.

Document patient is ≥ 1 year of age.
List prior or concomitant ASMs trialed (or evidence of response if currently receiving Epidiolex).
Document that Epidiolex is prescribed by or in consultation with a neurologist.

Denial Risk

Denial triggers for not meeting criteria

Requests that do not meet the policy's medical necessity criteria may be denied, including failures to meet age requirements, the required prior/concomitant ASM trials, prescriber specialty/consultation, or lack of evidence of response for current users.

Age < 1 year does not meet the criteria.
No documentation of ≥2 prior/concomitant ASMs (or qualifying alternative agents where specified) is a denial risk.
Medication not prescribed by or in consultation with a neurologist is a denial risk.
For current users, absence of documented clinical response (reduced seizure severity, frequency, and/or duration) is a denial risk.

Background on Epidiolex and Indications

Epidiolex is the cannabidiol oral solution indicated for treatment of seizures associated with Dravet syndrome, Lennox‑Gastaut syndrome, and tuberous sclerosis complex in patients aged ≥ 1 year. These conditions are severe, often treatment‑resistant pediatric epilepsy syndromes that frequently require combinations of antiseizure medications and specialized management.

Per the policy, prior authorization is recommended for prescription benefit coverage of Epidiolex and approvals are generally provided for a duration of 1 year when medical necessity criteria are met. Initial therapy criteria require the patient to be at least 1 year of age and to have tried or be concomitantly receiving at least two other antiseizure medications (or specified alternatives), with the prescription provided by or in consultation with a neurologist; continuation requests must document that the patient is responding to therapy (for example, reduced seizure frequency, severity, or duration).

Key Definitions

inv-12: Epidiolex — Cannabidiol oral solution indicated for seizures associated with Dravet syndrome, Lennox‑Gastaut syndrome, and tuberous sclerosis complex.

DrugEpidiolex (cannabidiol oral solution)

FDA‑approved indicationsSeizures associated with Dravet syndrome, Lennox‑Gastaut syndrome, and tuberous sclerosis complex

Minimum patient age≥ 1 year of age

Typical approval duration (when criteria met)Approve for 1 year

Policy requirementPrior authorization is recommended/required for prescription benefit coverage

Policy Summary

PayerCigna

PolicyAntiseizure Medications - Epidiolex Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateFeb 11, 2026

SourceLink

On This Page

OpenPayer

Antiseizure Medications - Epidiolex Prior Authorization Policy

Coverage Criteria for Epidiolex (cannabidiol)

Medication and Billing Codes

Prescriber Responsibilities and Authorization Rules

Background on Epidiolex and Indications

Key Definitions